Estimating cure proportion in cancer clinical trials using flexible parametric cure models.

ABSTRACT:

Background

In the context of survival analysis in recent cancer clinical trials, there has been an increasing interest in the proportion of patients who are not susceptible to the event, known as the cure proportion. To estimate it, cure models implicitly specify the time point when patients are considered cured, although the impact of the cure point position on cure proportion estimates is unclear.

Methods

Sensitivity of cure proportion estimates to the knot number and placement in flexible parametric cure models was examined using data from a clinical trial of CheckMate 141, an immuno-oncology compound. The performance of the model and procedures to determine the cure point position were evaluated using a simulation study.

Results

Analysis of the CheckMate 141 data

SUBMITTER: Sano Y 

PROVIDER: S-EPMC11524124 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature